Potomac Urology Center presents largest single center study of Aquablation
May 17th 2024"In our commercial all-comers cohort of patients undergoing Aquablation, efficacy was similar to and safety was improved compared to the WATER I and WATER II clinical trials," says Shawn H. Marhamati, MD, MS.
Dr. Bernie on testosterone therapy for men on active surveillance
May 15th 2024“The 2018 AUA guidelines for testosterone therapy that were co-chaired by Dr. John P. Mulhall say that we have an absence or a paucity of data on using testosterone therapy on active surveillance,” says Helen L. Bernie, DO, MPH.
Future research directions following study of UTI rates in transgender women post-vaginoplasty
May 14th 2024"We did discuss a couple of future research ideas, a number of which would have been controlling for those potential factors we thought could contribute to the increased UTI risk that we were not able to control for in the study like loss of commensal bacteria or anything of that nature," says David Gilbert.
Dr. Soon-Shiong highlights data on N-803 in NMIBC
May 13th 2024"But more excitingly, as early as 9 months, even though they were small numbers, the comparison between BCG and Anktiva vs BCG alone showed a statistical significance in the duration of ongoing complete response," says Patrick Soon-Shiong, MD.
Variability in treatment of node-positive prostate cancer after RP suggests QI opportunities
May 13th 2024"The wide variability that we found across MUSIC practices suggests an opportunity for us for quality improvement initiatives and additional evidence surrounding who should receive secondary treatment and what modalities," says Daniel A. Triner, MD, PhD.
Dr. Kutikov on retroperitoneoscopic partial nephrectomy for RCC
May 9th 2024“Also, the technique lends itself really nicely to these, what we call posterior ball-valve tumors, which are these tumors that sit behind the renal hilum, behind the blood vessels on the posterior side of the kidney,” says Alexander Kutikov, MD, FACS.
Dr. Psutka describes a study of at-home prehabilitation in MIBC
May 6th 2024"We've developed the Get Moving Trial, which is a randomized controlled phase 1/2 trial to demonstrate the safety, feasibility and efficacy of a home-based pre-op program that is personalized," says Sarah P. Psutka, MD, MSc.
Dr. Li on the design of the phase 3 MoonRISe-1 trial in NMIBC
May 6th 2024"So, in the MoonRISe-1 study, we're studying the efficacy of TAR-210 to prevent recurrence within the bladder by inserting the TAR-210 in the bladder every 3 months for up to 1 year, compared to intravesical chemotherapy," says Roger Li, MD.
Dr. Meeks highlights the recent innovation in bladder cancer
May 4th 2024"BCG worked well enough that we could give it to patients and it worked pretty well. But having the shortage, I think, has ultimately led to a bottleneck and then an explosion in the technology and the resources and the techniques to treat patients with non–muscle-invasive bladder cancer," says Joshua J. Meeks, MD, PhD.
Dr. Patel on a study comparing diagnostic approaches for renal masses
May 3rd 2024Hiten D. Patel, MD, highlights the background and trial design for the study, “A Prospective Diagnostic Cohort Study to Compare the Accuracy of Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients with Clinically Localized Renal Tumors (BIOPSy)."
Gem-doce and BCG yield similar outcomes for upper tract urothelial cell carcinoma
May 1st 2024"Ultimately, we found that in this retrospective evaluation, there was no significant difference in recurrence-free survival in those who are treated with gemcitabine and docetaxel as compared to BCG," says Ryan L. Steinberg, MD.
Expert on future directions for targeted therapy in urothelial carcinoma
April 30th 2024“There is great interest in looking at all these targeted interventions in the earlier stages to lower the burden of care that patients go through and to some degree that urologists and other health care professionals in this in this realm go through,” says Surena F. Matin, MD.